IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer

CAESAREA, Israel, Sept. 20, 2023 -- (Healthcare Sales & Marketing Network) -- IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to su... Devices, FDA IceCure Medical, ProSense System, cryoablation
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news